Clinical trials: Cohort Study
Breast Cancer
Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
The need to understand LABC is especially compelling in populations and countries with limited resources, where breast cancer incidence is relatively low, but mortality is comparably high.
- Trial name
- NCT02280252
- Testing
- Paclitaxel, Radiation therapy
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- NYU Langone Health
Uncomplicated Plasmodium Falciparum Malaria
Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria
This study aimed to determine the efficacy, safety and tolerability of the investigational drug KAF156 in combination with a solid dispersion formulation of lumefantrine (LUM-SDF) in pediatric patients (6 months to < 18 years of…
- Trial name
- KALUMI (NCT04546633)
- Testing
- KAF156, LUM-SDF, Coartem
- Where
- 9 sites in Burkina Faso, Côte d’Ivoire and 3 more
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Hepatic Impairment, Healthy Volunteers
Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma PK of PF-06865571.
- Trial name
- NCT04091061
- Testing
- PF-06865571 100 mg
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hematologic Neoplasms
A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies
The primary objective of this study is to characterize the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD) of relatlimab administered alone or in combination with nivolumab to subjects with…
- Trial name
- NCT02061761
- Testing
- BMS-986016, BMS-936558
- Where
- 10 sites in United States, Canada
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
Chemotherapy-induced Nausea and Vomiting
Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)
The purpose of this study was to determine the appropriate dosing regimen of fosaprepitant, when administered with ondansetron (with or without dexamethasone), for the prevention of CINV in children from birth to <17 years of…
- Trial name
- NCT01697579
- Testing
- Fosaprepitant, Ondansetron, 5-hydroxytryptamine 3 antagonist
- Volunteers
- 240 people
- Sponsor
- Merck Sharp & Dohme LLC
Insurance Status/Stability
IMPACCT for Kids' Care
Health insurance is important for children. Public insurance programs are available to many children, but some families report being confused about how to get and keep this insurance.
- Trial name
- IMPACCT (NCT02298361)
- Testing
- Health insurance outreach IT tools
- Volunteers
- 27,251 people, healthy volunteers welcome
- Sponsor
- OCHIN, Inc.
Spinal Cord Injuries
Spinal Cord Injury Program in Exercise
The purpose of this study is to examine two 8-week, remotely delivered exercise interventions: Movement-to-Music (M2M) and Standard Exercise Training (SET), with 327 adults with spinal cord injury.
- Trial name
- SCIPE (NCT03925077)
- Testing
- Movement-to-Music, Standard Exercise Training
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- University of Alabama at Birmingham
Stress, Psychological
The Impact of 8 Weeks of Digital Meditation Application and Healthy Eating Program on Work Stress and Health Outcomes
The aim of the present study is to test the effects of a digital meditation intervention and/or a healthy eating intervention in a sample of UCSF employees with overweight and obesity (BMI>=25kg/m2) who report mild to moderate…
- Conditions
- Stress, Psychological, Behavioral Symptoms, Sleep
- Trial name
- SFUC+Health (NCT03945214)
- Testing
- Meditation, Healthy Eating, Meditation + healthy eating
- Where
- United States
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Cancer Malignancies
Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort
Primary objective: 1. To examine the efficacy of melatonin treatment on neurocognitive functioning in adult survivors of childhood cancer. Secondary objectives: 1.
- Trial name
- NCT01700959
- Testing
- melatonin
- Where
- United States
- Volunteers
- 911 people
- Sponsor
- St. Jude Children's Research Hospital
Recurrent Glioblastoma
A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients
The purpose of the study is to compare the efficacy and safety of nivolumab administered alone versus bevacizumab in patients diagnosed with recurrent glioblastoma (a type of brain cancer, also known as GBM), and to evaluate the…
- Trial name
- CheckMate 143 (NCT02017717)
- Testing
- Nivolumab, Bevacizumab, Ipilimumab
- Where
- 112 sites in United States, Australia and 10 more
- Volunteers
- 529 people
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis
D2212C00002 J-Phase II Study
The purpose of the study is to evaluate the safety and tolerability of multiple-doses of tralokinumab in Japanese patients with Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT02036580
- Testing
- tralokinumab cohort 1, tralokinumab cohort 2
- Where
- 5 sites in Japan
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Human Immunodeficiency Virus
A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)
A study to test the safety and effect of twice daily raltegravir in a diverse cohort of patients currently infected with human immunodeficiency virus (HIV), where at least 50% are African American and at least 25% are female…
- Trial name
- NCT00764946
- Testing
- Comparator: raltegravir
- Volunteers
- 209 people
- Sponsor
- Merck Sharp & Dohme LLC
Age-Related Macular Degeneration
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
The purpose of the study is to evaluate the safety, tolerability, immunogenicity, and bioactivity of a single intravitreal (IVT) administration of DE-122 in subjects with refractory exudative age-related macular degeneration…
- Trial name
- PAVE (NCT02555306)
- Testing
- 0.5 mg of DE-122, 1.0 mg of DE-122, 2.0 mg of DE-122
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Santen Inc.
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)
This is a multi-center, Phase III study to evaluate the safety and tolerability of proposed dose conversion recommendations for RLS subjects converting from ropinirole immediate release to ropinirole controlled-release for RLS.
- Trial name
- NCT00256854
- Testing
- Ropinirole IR 1 mg, Ropinirole IR 2 mg, Ropinirole CR 2 mg
- Where
- 30 sites in United States
- Volunteers
- 135 people
- Sponsor
- GlaxoSmithKline
Neoplasms
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
This study will evaluate the combination of a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, niraparib, with the programmed cell death protein 1 (PD-1) inhibitor, dostarlimab in the paediatric population.
- Trial name
- NCT04544995
- Testing
- Niraparib (Tablet for oral suspension), Dostarlimab, Niraparib (Tablet)
- Where
- 2 sites in United Kingdom
- Volunteers
- 47 people
- Sponsor
- GlaxoSmithKline
Submental Fat
A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.
Twenty-Eight (28) subjects (12 for cohort 1 and 16 for cohort 2 ) will be included in the study. Subjects in each cohort will be injected with a different dose of RZL-012.
- Trial name
- NCT04086823
- Testing
- RZL-012
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Raziel Therapeutics Ltd.
Pleural Mesothelioma, Non-small Cell Lung Cancer
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
The Primary Objective was: -To determine the antitumor activity of SAR444245 in combination with other anticancer therapies. The Secondary Objectives were: To confirm the dose and to assess the safety profile of SAR444245 when…
- Trial name
- NCT04914897
- Testing
- THOR-707, Pembrolizumab
- Where
- 35 sites in United States, Argentina and 9 more
- Volunteers
- 106 people
- Sponsor
- Sanofi
Post-Resuscitation Syndrome, Critical Illness
Predicting Mortality in Patients With Return of Spontaneous Circulation After Cardiac Arrest
This retrospective observational cohort study aims to identify early predictors of short- and mid-term mortality in adult patients who achieved return of spontaneous circulation (ROSC) after cardiac arrest.
- Conditions
- Post-Resuscitation Syndrome, Critical Illness, Cardiac Arrest, Hypoxic-Ischemic Encephalopathy
- Trial name
- PROM-ROSC (NCT07020091)
- Where
- Turkey (Türkiye)
- Volunteers
- 168 people
- Sponsor
- Ahmet Düzgün
Medulloblastoma, Childhood
177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma
Children and adolescents diagnosed with medullablastoma and with recurrent or refractory to frontline therapy will be treated with 177Lu-DTPA-omburtamab, which is a radioactive labelling of a murine monoclonal antibody targeting…
- Trial name
- NCT04167618
- Testing
- 177Lu-DTPA-omburtamab
- Where
- 10 sites in United States, Denmark and 3 more
- Volunteers
- 2 people
- Sponsor
- Y-mAbs Therapeutics
Breast Cancer, Mammographic Density
Karolinska Interventional Study of Mammograhic Density (Karisma-1)
A feasibility study, randomising to either 10 or 20 mg of tamoxifen. The primary aim is to identify the time to mammographic density change and piloting the procedures.
- Trial name
- Karisma-1 (NCT04079517)
- Testing
- Tamoxifen
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet